

**NAVANA PHARMACEUTICALS LIMITED**

Corporate Office : House # 99 Road #04 Block # B,  
Banani, Dhaka-1213

**PRICE SENSITIVE INFORMATION**

This is for kind information to all valued shareholders of Navana Pharmaceuticals Limited and stakeholders that the Board of Directors of the company in its 32nd meeting held on 14<sup>th</sup> November, 2023 ended at 4.00 p.m. has considered and approved, among others, the Un-audited Financial Statements for the first quarter (Q1) period ended on September 30, 2023 and took the following Price Sensitive Decision:-

**Comparative Statement on Un-audited Financial Statement for the first quarter (Q1, FY-2023-2024) period ended on September 30, 2023**

Sl. No	Particulars	01.07.2023-30.09.2023	01.07.2022-30.09.2022
i	Earnings Per Share (EPS)	1.11	0.91
ii	Net Operating Cash Flow Per Share (NOCFPS)	1.19	1.18
		<b>As at 30.09.2023</b>	<b>As at 30.06.2023</b>
iii	Net Asset Value (NAV)	4,482,779,472	4,372,445,072
iv	Net Asset Value Per Share	41.73	40.71

**Notes:****★ Reasons of significant deviation in earning per share (EPS) between the quarterly periods:**

- EPS: Increase in Sales Revenue and efficient usages of material resulted in increased gross profit for the reporting period resulted in the increment of Earnings per Share as well.

★ In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company is pleased to publish the Un-audited Financial Statement for the first quarter (Q1) period ended on September 30, 2023 in two widely circulated daily newspapers (one in Bengali and other one in English) and also in an online news portal. The detail of the published quarterly Financial Statements will be available in the website ([www.navanapharma.com](http://www.navanapharma.com)) of the company.

Dated: November 14, 2023

By order of the Board  
Sd/-

**Joynul Abedin ACS**  
Company Secretary